glp 1 off shortage list FDA's GLP-1 decision kicks 'unprecedented' tussle over Reality check: Unpacking the $150B

Integration coaching supports patients in processing insights gained during ketamine therapy sessions and applying them to real life

A negotiated settlement

The Outcome: A federal judge in the Northern District of Texas denied the OFAs motion for a preliminary injunction, affirming the FDAs decision.28 The court emphasized the agencys broad discretion in managing the drug shortage list and found that the plaintiffs had not demonstrated sufficient irreparable harm to warrant judicial intervention against the regulator

Science 270 (5239), 11661170

Bio-mimicking nanoparticles for targeted therapy of malignant melanoma